Jung Hyun Jo, M.D., M.Med., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biliary Tract Neoplasms | 6 | 2024 | 187 | 1.930 |
Why?
|
Cholestasis | 6 | 2023 | 385 | 1.550 |
Why?
|
Pancreatic Neoplasms | 19 | 2024 | 5443 | 1.550 |
Why?
|
Carcinoma, Pancreatic Ductal | 10 | 2024 | 1755 | 1.370 |
Why?
|
Bile Duct Neoplasms | 5 | 2023 | 616 | 1.030 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 5 | 2024 | 520 | 0.930 |
Why?
|
Neoplastic Stem Cells | 2 | 2021 | 1356 | 0.800 |
Why?
|
Cholangiocarcinoma | 4 | 2023 | 562 | 0.680 |
Why?
|
Sodium Compounds | 1 | 2018 | 35 | 0.640 |
Why?
|
Arsenites | 1 | 2018 | 65 | 0.630 |
Why?
|
Microfilament Proteins | 1 | 2024 | 1135 | 0.620 |
Why?
|
Gallstones | 2 | 2023 | 285 | 0.530 |
Why?
|
Drainage | 3 | 2021 | 1184 | 0.490 |
Why?
|
Endosonography | 1 | 2018 | 622 | 0.470 |
Why?
|
Specimen Handling | 1 | 2018 | 708 | 0.450 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 2013 | 138 | 0.410 |
Why?
|
Stents | 6 | 2022 | 3201 | 0.410 |
Why?
|
Republic of Korea | 7 | 2020 | 587 | 0.400 |
Why?
|
Salvage Therapy | 1 | 2018 | 1277 | 0.390 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 11854 | 0.390 |
Why?
|
Deoxycytidine | 4 | 2022 | 888 | 0.370 |
Why?
|
Endoscopy | 2 | 2019 | 1857 | 0.340 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3610 | 0.330 |
Why?
|
Adenocarcinoma | 3 | 2022 | 6406 | 0.330 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1060 | 0.320 |
Why?
|
Spheroids, Cellular | 2 | 2021 | 331 | 0.310 |
Why?
|
Carrier Proteins | 1 | 2021 | 4936 | 0.310 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1484 | 0.310 |
Why?
|
Preoperative Care | 1 | 2016 | 2258 | 0.280 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2025 | 138 | 0.240 |
Why?
|
Gene Silencing | 2 | 2021 | 1503 | 0.220 |
Why?
|
Survivors | 1 | 2014 | 2382 | 0.220 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6541 | 0.220 |
Why?
|
Cholestasis, Extrahepatic | 1 | 2022 | 52 | 0.210 |
Why?
|
Cholangitis | 1 | 2023 | 110 | 0.200 |
Why?
|
Disease-Free Survival | 5 | 2021 | 6856 | 0.200 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 13697 | 0.190 |
Why?
|
CA-19-9 Antigen | 1 | 2021 | 107 | 0.190 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2023 | 304 | 0.190 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2909 | 0.190 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17135 | 0.180 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 196 | 0.180 |
Why?
|
Mice, Inbred NOD | 2 | 2021 | 1839 | 0.170 |
Why?
|
Mesenteric Veins | 1 | 2020 | 87 | 0.170 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2025 | 755 | 0.170 |
Why?
|
Peritoneal Neoplasms | 2 | 2018 | 715 | 0.170 |
Why?
|
Chromogranin A | 1 | 2019 | 47 | 0.160 |
Why?
|
Mice, SCID | 2 | 2021 | 2632 | 0.160 |
Why?
|
Pancreatic Pseudocyst | 1 | 2019 | 112 | 0.160 |
Why?
|
Pancreatitis | 2 | 2018 | 1087 | 0.160 |
Why?
|
Muscle Proteins | 1 | 2024 | 1165 | 0.150 |
Why?
|
Cell Proliferation | 4 | 2025 | 10478 | 0.150 |
Why?
|
Cell Movement | 2 | 2021 | 5215 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2025 | 4921 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2021 | 567 | 0.140 |
Why?
|
Portal Vein | 1 | 2020 | 432 | 0.140 |
Why?
|
Leucovorin | 2 | 2020 | 643 | 0.140 |
Why?
|
Gallbladder Neoplasms | 1 | 2018 | 191 | 0.140 |
Why?
|
Middle Aged | 20 | 2024 | 223491 | 0.140 |
Why?
|
Biosensing Techniques | 1 | 2023 | 661 | 0.130 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14737 | 0.130 |
Why?
|
Humans | 39 | 2025 | 768393 | 0.130 |
Why?
|
Matrix Metalloproteinases | 1 | 2019 | 393 | 0.130 |
Why?
|
Male | 22 | 2024 | 364902 | 0.120 |
Why?
|
Treatment Outcome | 10 | 2024 | 65379 | 0.120 |
Why?
|
Metals | 1 | 2019 | 713 | 0.120 |
Why?
|
Prognosis | 10 | 2024 | 30022 | 0.120 |
Why?
|
Sequence Analysis, RNA | 2 | 2021 | 2038 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5891 | 0.120 |
Why?
|
Aged | 15 | 2024 | 171562 | 0.110 |
Why?
|
Fluorouracil | 2 | 2020 | 1655 | 0.110 |
Why?
|
Gastric Outlet Obstruction | 1 | 2014 | 55 | 0.110 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 408 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2460 | 0.100 |
Why?
|
Neuroendocrine Tumors | 1 | 2019 | 658 | 0.100 |
Why?
|
Retrospective Studies | 12 | 2024 | 81801 | 0.100 |
Why?
|
Female | 21 | 2024 | 397089 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2021 | 3434 | 0.100 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2014 | 119 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2884 | 0.100 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12558 | 0.100 |
Why?
|
Gastroesophageal Reflux | 1 | 2019 | 835 | 0.100 |
Why?
|
Anesthesia | 1 | 2023 | 1596 | 0.100 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2206 | 0.090 |
Why?
|
Cisplatin | 1 | 2017 | 1661 | 0.090 |
Why?
|
Decompression, Surgical | 1 | 2016 | 610 | 0.090 |
Why?
|
Camptothecin | 1 | 2014 | 593 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4859 | 0.090 |
Why?
|
Administration, Oral | 1 | 2018 | 4039 | 0.090 |
Why?
|
Propensity Score | 3 | 2024 | 1962 | 0.090 |
Why?
|
Acute Coronary Syndrome | 1 | 2023 | 2192 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11254 | 0.090 |
Why?
|
Liver Transplantation | 1 | 2021 | 2400 | 0.080 |
Why?
|
Pancreatectomy | 2 | 2024 | 824 | 0.080 |
Why?
|
Cohort Studies | 6 | 2023 | 41795 | 0.070 |
Why?
|
Quinazolines | 1 | 2014 | 1373 | 0.070 |
Why?
|
Risk Factors | 7 | 2023 | 74962 | 0.070 |
Why?
|
Causality | 1 | 2013 | 1255 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2020 | 2776 | 0.070 |
Why?
|
Tumor Microenvironment | 3 | 2025 | 3939 | 0.070 |
Why?
|
Incidence | 3 | 2023 | 21544 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12092 | 0.070 |
Why?
|
Physicians | 1 | 2024 | 4614 | 0.060 |
Why?
|
Gastric Bypass | 1 | 2014 | 829 | 0.060 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 1030 | 0.060 |
Why?
|
Neoplasms | 2 | 2025 | 22385 | 0.060 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 2024 | 44 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5336 | 0.050 |
Why?
|
MicroRNAs | 1 | 2019 | 3804 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8634 | 0.050 |
Why?
|
Survival Rate | 3 | 2024 | 12870 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2014 | 8562 | 0.050 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1568 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2018 | 4365 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9433 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54920 | 0.050 |
Why?
|
Cholecystectomy | 1 | 2023 | 409 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16721 | 0.040 |
Why?
|
Time Factors | 2 | 2020 | 40272 | 0.040 |
Why?
|
Mice | 3 | 2022 | 82017 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 167 | 0.040 |
Why?
|
Palliative Care | 3 | 2022 | 3643 | 0.040 |
Why?
|
Mesenteric Arteries | 1 | 2020 | 178 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13503 | 0.040 |
Why?
|
Animals | 5 | 2025 | 169337 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2020 | 20765 | 0.040 |
Why?
|
Comorbidity | 1 | 2013 | 10588 | 0.040 |
Why?
|
Catheterization | 1 | 2024 | 1431 | 0.040 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2023 | 446 | 0.040 |
Why?
|
Antibiotic Prophylaxis | 1 | 2023 | 640 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2021 | 993 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2021 | 1104 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2020 | 1004 | 0.040 |
Why?
|
Preoperative Period | 1 | 2019 | 564 | 0.030 |
Why?
|
Laparotomy | 1 | 2019 | 459 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8731 | 0.030 |
Why?
|
Living Donors | 1 | 2021 | 651 | 0.030 |
Why?
|
Motion | 1 | 2019 | 789 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 22296 | 0.030 |
Why?
|
Albumins | 1 | 2018 | 577 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 682 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2018 | 302 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13323 | 0.030 |
Why?
|
Temperature | 1 | 2020 | 2235 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6132 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13576 | 0.030 |
Why?
|
Nutritional Status | 1 | 2021 | 1627 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1766 | 0.030 |
Why?
|
Transplantation, Heterologous | 1 | 2021 | 2394 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 893 | 0.030 |
Why?
|
Adult | 5 | 2020 | 223640 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2533 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2020 | 3633 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1890 | 0.020 |
Why?
|
Hemorrhage | 1 | 2024 | 3461 | 0.020 |
Why?
|
Cell Survival | 1 | 2021 | 5792 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2016 | 59686 | 0.020 |
Why?
|
Lipase | 1 | 2013 | 321 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2020 | 3230 | 0.020 |
Why?
|
Paclitaxel | 1 | 2018 | 1736 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2948 | 0.020 |
Why?
|
Norepinephrine | 1 | 2013 | 900 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3666 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9510 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1830 | 0.020 |
Why?
|
Cardiopulmonary Bypass | 1 | 2013 | 1097 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10117 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6318 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2018 | 1664 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3543 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39407 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5916 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2014 | 2126 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9614 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 13042 | 0.020 |
Why?
|
Ultrasonography | 1 | 2019 | 6001 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7445 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6808 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9682 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 2017 | 1943 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7463 | 0.010 |
Why?
|
Models, Statistical | 1 | 2019 | 5099 | 0.010 |
Why?
|
Transcription Factors | 1 | 2024 | 12166 | 0.010 |
Why?
|
Registries | 1 | 2020 | 8379 | 0.010 |
Why?
|
Swine | 1 | 2014 | 5994 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13646 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18471 | 0.010 |
Why?
|
Acute Disease | 1 | 2013 | 7242 | 0.010 |
Why?
|
Signal Transduction | 1 | 2025 | 23631 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 16028 | 0.010 |
Why?
|
Cardiac Surgical Procedures | 1 | 2013 | 3681 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18362 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36849 | 0.010 |
Why?
|